Description: Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Home Page: www.oryzon.com
Sant Ferran 74
Cornellà de Llobregat,
08940
Spain
Phone:
34 93 515 13 13
Officers
| Name | Title |
|---|---|
| Dr. Carlos Manuel Buesa Arjol | Co-Founder, Chairman, CEO & President |
| Mr. Enric Rello Condomines | COO & CFO |
| Mr. Jordi Xaus Pey | Scientific Director |
| Mr. Xavier Perpinya Ribera | Head of Internal Audit & Compliance |
| Mr. Augusto Pinel Rubio | Secretary |
| Mr. Emili Torrell Cortada | Director of Business Development |
| Ms. Neus Virgili Bernado | Director of Industrial Property |
| Dr. Michael Thomas Ropacki Ph.D. | Medical Director of SNC |
| Ms. Sonia Paloma Gutierrez Bezon | Director of Clinical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 8.0775 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9888 |
| Price-to-Sales TTM: | 6.1392 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 46 |